0001558370-22-014511.txt : 20220921 0001558370-22-014511.hdr.sgml : 20220921 20220921080013 ACCESSION NUMBER: 0001558370-22-014511 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20220921 DATE AS OF CHANGE: 20220921 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AYTU BIOPHARMA, INC CENTRAL INDEX KEY: 0001385818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 470883144 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38247 FILM NUMBER: 221255027 BUSINESS ADDRESS: STREET 1: 373 INVERNESS PARKWAY STREET 2: SUITE 206 CITY: ENGLEWOOD STATE: CO ZIP: 80112 BUSINESS PHONE: (720) 437-6580 MAIL ADDRESS: STREET 1: 373 INVERNESS PARKWAY STREET 2: SUITE 206 CITY: ENGLEWOOD STATE: CO ZIP: 80112 FORMER COMPANY: FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC DATE OF NAME CHANGE: 20150609 FORMER COMPANY: FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC. DATE OF NAME CHANGE: 20150609 FORMER COMPANY: FORMER CONFORMED NAME: Rosewind CORP DATE OF NAME CHANGE: 20070110 DEFA14A 1 tmb-20220921xdefa14a.htm DEFA14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 14A

(RULE 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(A) of the

Securities Exchange Act of 1934

Filed by the Registrant 

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to § 240.14a-12

Aytu BioPharma, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee paid previously with preliminary materials.

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.


Graphic

**** IMPORTANT REMINDER ****

Dear Aytu BioPharma, Inc. Stockholder:

By now, you should have received your proxy material for the Aytu BioPharma, Inc. Special Meeting which is scheduled to be held on October 5, 2022.  You are receiving this reminder letter because your votes were not yet processed at the time that this letter was mailed.  If you have already voted, we would like to thank you for your vote.

****PLEASE VOTE TODAY****

Your Board recommends that you vote FOR proposals 1, and 2. Even if you plan on attending the meeting, we urge you to vote your shares now, so they can be tabulated prior to the meeting.

Your vote is extremely important.  PLEASE CAST YOUR VOTE TODAY.  The fastest and easiest way to vote is by telephone or over the Internet.  Instructions on how to vote your shares over the telephone or Internet are enclosed with this letter.  Alternatively, you may sign and return the enclosed voting form in the envelope provided.

If you sign and return the enclosed voting form without indicating a different choice your shares will be voted as recommended by your Board of Directors.

WE URGE YOU TO EXERCISE YOUR RIGHT TO VOTE TODAY.

If you have questions or need help voting your shares, please call our proxy solicitation firm, Morrow Sodali LLC at 1-800-607-0088.

Thank you for your investment in Aytu BioPharma, Inc. and for taking the time to vote your shares.

Sincerely,

Joshua Disbrow

Chairman and Chief Executive Officer


GRAPHIC 2 tmb-20220921xdefa14a001.jpg GRAPHIC begin 644 tmb-20220921xdefa14a001.jpg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end